Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724289 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin for Prolonged Grief Disorder
A Early Phase 1 study of Prolonged Grief Disorder, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06724289: Recruiting Early Phase 1 study of Prolonged Grief Disorder, sponsored by University of Virginia.
NCT06724289 is a Early Phase 1 study of Prolonged Grief Disorder that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 12 participants, below the 208-participant average among 3 other Prolonged Grief Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06724289, a Early Phase 1 study of Prolonged Grief Disorder, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
Primary Outcome
Number of participants enrolled divided by number screened over the recruitment period.
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
- DIAGNOSTIC_TEST Functional Magnetic Resonance Imaging (fMRI)
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-08 |
| Phase | Early Phase 1 |
What NCT06724289 shows while recruiting
NCT06724289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 208-participant average among 3 other Prolonged Grief Disorder trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Prolonged Grief Disorder appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin 25 mg is the first listed.
NCT06724289 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06724289 about?
NCT06724289 is a clinical study titled "Psilocybin for Prolonged Grief Disorder". The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
What is the current status of trial NCT06724289?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2027-08.
What conditions does trial NCT06724289 study?
This clinical trial studies the following conditions: Prolonged Grief Disorder.
What interventions are being tested in trial NCT06724289?
The interventions under investigation include: Psilocybin 25 mg (DRUG), Functional Magnetic Resonance Imaging (fMRI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06724289?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724289 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prolonged Grief Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia